Genmab A/S (GMAB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genmab A/S (GMAB) trades at $25.26 with AI Score 58/100 (Grade B). Genmab A/S is a biotechnology company specializing in the creation and development of antibody therapeutics for cancer and other diseases. Market cap: $15.51B, Sector: Healthcare.
Last analyzed: Mar 15, 2026GMAB stock analysis for 2026: Analysts have set a consensus price target of $40.17 for Genmab A/S, suggesting 59.0% upside from the current price of $25.26. The AI MoonshotScore is 58/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GMAB: 1/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Genmab A/S (GMAB) Healthcare & Pipeline Overview
Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases, marketing key products like DARZALEX and teprotumumab. With a robust pipeline and strategic collaborations, Genmab aims to address unmet medical needs in oncology and immunology, holding a strong position in the antibody therapeutics market.
What Is the Investment Thesis for GMAB?
Genmab A/S presents a compelling investment case driven by its robust pipeline of antibody therapeutics and strategic partnerships. The company's marketed products, including DARZALEX and teprotumumab, generate substantial revenue, reflected in a profit margin of 16.7% and a gross margin of 93.6%. Key growth catalysts include the advancement of its Phase 2 clinical programs and potential regulatory approvals for novel therapies. The company's collaboration agreements with industry leaders like AbbVie and Janssen further de-risk its development pipeline. However, potential risks include clinical trial failures and increased competition in the biotechnology sector. With a market capitalization of $16.11 billion and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market presence.
Based on FMP financials and quantitative analysis
GMAB Key Highlights
- Market capitalization of $16.11 billion, indicating a strong market valuation.
- P/E ratio of 25.88, reflecting investor expectations for future earnings growth.
- Profit margin of 16.7%, demonstrating efficient operations and profitability.
- Gross margin of 93.6%, showcasing the high value of its therapeutic products.
- Beta of 0.75, suggesting lower volatility compared to the overall market.
Who Are GMAB's Competitors?
GMAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | $203.67 | -0.08% | $22.55B | 49 |
| EXEL Exelixis, Inc. | $53.54 | +0.07% | $13.46B | 55 |
| ILMN Illumina, Inc. | $162.23 | -2.39% | 25B | 58 |
| INCY Incyte Corporation | $108.53 | +0.65% | 22B | 64 |
| ROIV Roivant Sciences Ltd. | $30.27 | +1.82% | $21.77B | 39 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GMAB's Key Strengths?
- Strong portfolio of marketed products, including DARZALEX and teprotumumab.
- Robust pipeline of antibody therapeutics in clinical development.
- Strategic collaborations with leading pharmaceutical companies.
- High gross margin of 93.6%.
What Are GMAB's Weaknesses?
- Reliance on a limited number of key products for revenue generation.
- High research and development expenses.
- Potential for clinical trial failures.
- Exposure to regulatory risks.
What Could Drive GMAB Stock Higher?
- Regulatory approval decisions for Teclistamab in relapsed/refractory multiple myeloma.
- Data readouts from Phase 2 clinical trials for Camidanlumab tesirine in Hodgkin lymphoma and solid tumors.
- Expansion of DARZALEX into new indications, including non-MM blood cancers and AL amyloidosis.
- Strategic collaborations with pharmaceutical companies to develop and commercialize new antibody therapeutics.
What Are the Key Risks for GMAB?
- Clinical trial failures for key pipeline candidates.
- Increased competition in the antibody therapeutics market.
- Patent expirations for key products.
- Regulatory risks associated with drug development and commercialization.
- Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Danish Krone.
What Are the Growth Opportunities for GMAB?
- Expansion of DARZALEX into New Indications: DARZALEX, Genmab's flagship product for multiple myeloma, has the potential for expansion into new indications, including non-MM blood cancers and AL amyloidosis. This expansion could significantly increase revenue streams and market share. The market for multiple myeloma therapeutics is projected to reach $37.5 billion by 2030, providing a substantial growth opportunity for Genmab.
- Advancement of Phase 2 Clinical Programs: Genmab has several promising products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, and Mim8. Successful completion of these trials and subsequent regulatory approvals could lead to the launch of new blockbuster drugs. The timeline for these approvals is estimated to be within the next 3-5 years, offering a near-term growth catalyst.
- Strategic Collaborations and Partnerships: Genmab's collaboration agreements with industry leaders like AbbVie, Janssen, and BioNTech provide access to cutting-edge technologies and resources. These partnerships de-risk the development pipeline and accelerate the commercialization of new therapies. The value of these collaborations is estimated to be in the billions of dollars, offering a significant boost to Genmab's long-term growth prospects.
- Geographic Expansion into Emerging Markets: Genmab has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These markets offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer and autoimmune diseases. The timeline for this expansion is estimated to be within the next 5-10 years.
- Development of Next-Generation Antibody Therapeutics: Genmab is actively engaged in the development of next-generation antibody therapeutics, including bispecific antibodies and antibody-drug conjugates. These innovative therapies have the potential to revolutionize the treatment of cancer and other diseases. The market for bispecific antibodies is projected to reach $12.4 billion by 2028, providing a substantial growth opportunity for Genmab.
What Opportunities Does GMAB Have?
- Expansion into new therapeutic areas.
- Geographic expansion into emerging markets.
- Development of next-generation antibody therapeutics.
- Acquisition of complementary technologies or companies.
What Threats Does GMAB Face?
- Competition from other biotechnology and pharmaceutical companies.
- Patent expirations.
- Pricing pressures.
- Changes in healthcare regulations.
What Are GMAB's Competitive Advantages?
- Proprietary antibody technology platforms.
- Strong intellectual property protection.
- Established partnerships with leading pharmaceutical companies.
- Deep expertise in antibody therapeutics development.
What Does GMAB Do?
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's evolution has been marked by strategic collaborations and a focus on innovative research and development. Genmab markets DARZALEX, a human monoclonal antibody for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its diverse product portfolio includes daratumumab for MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for hematological malignancies. Genmab also has approximately 20 active pre-clinical programs and several products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. The company has established collaborations with CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc., enhancing its research and development capabilities. Genmab's commitment to innovation and strategic partnerships positions it as a key player in the antibody therapeutics market.
What Products and Services Does GMAB Offer?
- Develops antibody therapeutics for cancer and other diseases.
- Markets DARZALEX for the treatment of multiple myeloma (MM).
- Markets teprotumumab for the treatment of thyroid eye disease.
- Develops ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis.
- Develops Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Conducts Phase 2 clinical trials for various therapeutic candidates.
- Engages in pre-clinical research and development programs.
How Does GMAB Make Money?
- Develops and commercializes antibody therapeutics.
- Generates revenue through product sales and royalties.
- Collaborates with other pharmaceutical companies for research and development.
- Out-licenses its technologies and products to partners.
What Industry Does GMAB Operate In?
Genmab A/S operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for antibody therapeutics is experiencing substantial growth, driven by the increasing prevalence of cancer and autoimmune diseases. Key competitors include companies like DGX, EXEL, ILMN, INCY, and ROIV, each vying for market share with their own unique therapeutic approaches. Genmab distinguishes itself through its focus on differentiated antibody therapeutics and strategic collaborations, positioning it to capitalize on the growing demand for innovative treatments.
Who Are GMAB's Key Customers?
- Patients with cancer and other diseases.
- Hospitals and clinics.
- Pharmaceutical companies.
- Healthcare providers.
GMAB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Genmab's future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative pipeline and potential breakthrough therapies.
- Analysts have noted increasing interest in Genmab's collaborations, which could enhance its market position and drive future revenue.
- The recent advancements in clinical trials have generated excitement, positioning Genmab as a leader in its field and attracting attention from investors.
Bear Case
- Concerns over the competitive landscape are growing, with rivals advancing in similar therapeutic areas, potentially impacting Genmab's market share.
- Some community members express skepticism about the sustainability of Genmab's recent successes, fearing that hype may overshadow fundamental issues.
- Recent regulatory hurdles faced by biotech companies have raised caution among investors, leading to a more bearish sentiment around Genmab's prospects.
- Market perception remains cautious due to broader economic uncertainties, which may impact funding and investment in biotech sectors, including Genmab.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GMAB Latest News
-
Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits
MT Newswires · Jun 11, 2026
-
Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups
benzinga · Jun 11, 2026
-
Grant of Restricted Stock Units and Warrants to Employees in Genmab
globenewswire.com · Jun 11, 2026
-
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
globenewswire.com · Jun 11, 2026
GMAB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GMAB.
Price Targets
Consensus target: $40.17
GMAB MoonshotScore
What does this score mean?
The MoonshotScore rates GMAB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits
Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Latest Genmab A/S Analysis
Leadership: Jan van de Winkel
Chief Executive Officer
Jan van de Winkel has served as the Chief Executive Officer of Genmab A/S, managing a workforce of 2638 employees. His career spans over two decades in the biotechnology and pharmaceutical industries. He holds a Ph.D. in Immunology from the University of Nijmegen and has authored numerous scientific publications. Prior to joining Genmab, he held leadership positions at various biotech companies, focusing on antibody therapeutics and drug development. His expertise lies in translating scientific discoveries into innovative treatments for cancer and other diseases.
Track Record: Under Jan van de Winkel's leadership, Genmab has achieved significant milestones, including the successful development and commercialization of DARZALEX and teprotumumab. He has overseen the expansion of Genmab's pipeline through strategic collaborations and acquisitions. His tenure has been marked by a focus on innovation and a commitment to developing differentiated antibody therapeutics. The company's market capitalization has grown substantially under his leadership, reflecting his strategic vision and execution.
Genmab A/S ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GMAB, as an ADR, allows U.S. investors to invest in Genmab A/S without the complexities of cross-border transactions. Each GMAB ADR represents a specific number of Genmab A/S shares traded on its home market, simplifying ownership and trading for U.S. investors.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Genmab A/S (GMAB) — Healthcare
What does Genmab A/S do?
Genmab A/S is a biotechnology company focused on the research, development, and commercialization of antibody therapeutics for the treatment of cancer and other diseases. The company's primary focus is on creating differentiated antibody products that address unmet medical needs. Genmab generates revenue through the sales of its marketed products, including DARZALEX and teprotumumab, as well as through royalties and milestone payments from its collaborations with other pharmaceutical companies. The company's business model is centered on innovation and strategic partnerships, allowing it to advance its pipeline of novel antibody therapeutics.
What do analysts say about GMAB stock?
Analyst consensus on GMAB stock is generally positive, reflecting the company's strong pipeline and established market presence. Key valuation metrics include a market capitalization of $16.11 billion and a P/E ratio of 25.88. Growth considerations include the potential for regulatory approvals for key pipeline candidates and the expansion of DARZALEX into new indications. Analysts also highlight the company's strategic collaborations and strong financial position as positive factors. However, potential risks include clinical trial failures and increased competition in the biotechnology sector. This is a neutral summary of analyst sentiment, not a recommendation to buy or sell.
What are the main risks for GMAB?
The main risks for Genmab A/S include clinical trial failures, which could significantly impact the company's pipeline and future revenue potential. Increased competition in the antibody therapeutics market poses a threat to the company's market share and pricing power. Patent expirations for key products could lead to generic competition and reduced revenue. Regulatory risks associated with drug development and commercialization could delay or prevent the approval of new therapies. Currency risk, due to fluctuations in the exchange rate between the U.S. dollar and the Danish Krone, could impact the value of the company's ADR.
What are the key factors to evaluate for GMAB?
Genmab A/S (GMAB) holds an AI score of 58/100 (moderate). P/E: 18.6x vs the S&P 500's ~20-25x. Analysts target $40.17 (+59%). Not financial advice.
How frequently does GMAB data refresh on this page?
GMAB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GMAB's recent stock price performance?
Genmab A/S (GMAB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong portfolio of marketed products, including DARZALEX and teprotumumab. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GMAB overvalued or undervalued right now?
Genmab A/S (GMAB) trades at 18.6x earnings. Analysts target $40.17 (+59%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GMAB?
Before investing in Genmab A/S (GMAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of 2026-03-15.